Abstract
In recent years, a clear trend has been observed for taxanes to be used earlier in the course of breast cancer, with a large proportion of patients previously treated with anthracyclines and/or taxanes in the (neo)adjuvant setting. In addition, tolerability issues associated with taxane use in elderly patients and patients with substantial comorbidity, means that taxane use is frequently compromised in a substantial proportion of patients with metastatic breast cancer (MBC). Retreatment with taxanes yields variable results, and alternative cytotoxic agents with good activity in patients with anthracycline- and taxane-pretreated MBC are required. Large studies and meta-analyses have helped to establish the role of anthracycline- and taxane-based adjuvant therapy for early breast cancer (EBC). Addition of further cytotoxic agents has generally met with little success, thus the focus has moved towards optimization of adjuvant therapy through scheduling and patient selection. This review considers recent and ongoing developments in the chemotherapeutic management of EBC and MBC.
Keywords: Anthracyclines, capecitabine, chemotherapy, early breast cancer, metastatic breast cancer, taxanes.
Current Cancer Therapy Reviews
Title:Going Beyond Anthracyclines and Taxanes in Breast Cancer – What’s Next?
Volume: 9 Issue: 1
Author(s): Sunil Verma
Affiliation:
Keywords: Anthracyclines, capecitabine, chemotherapy, early breast cancer, metastatic breast cancer, taxanes.
Abstract: In recent years, a clear trend has been observed for taxanes to be used earlier in the course of breast cancer, with a large proportion of patients previously treated with anthracyclines and/or taxanes in the (neo)adjuvant setting. In addition, tolerability issues associated with taxane use in elderly patients and patients with substantial comorbidity, means that taxane use is frequently compromised in a substantial proportion of patients with metastatic breast cancer (MBC). Retreatment with taxanes yields variable results, and alternative cytotoxic agents with good activity in patients with anthracycline- and taxane-pretreated MBC are required. Large studies and meta-analyses have helped to establish the role of anthracycline- and taxane-based adjuvant therapy for early breast cancer (EBC). Addition of further cytotoxic agents has generally met with little success, thus the focus has moved towards optimization of adjuvant therapy through scheduling and patient selection. This review considers recent and ongoing developments in the chemotherapeutic management of EBC and MBC.
Export Options
About this article
Cite this article as:
Verma Sunil, Going Beyond Anthracyclines and Taxanes in Breast Cancer – What’s Next?, Current Cancer Therapy Reviews 2013; 9 (1) . https://dx.doi.org/10.2174/1573394711309010005
DOI https://dx.doi.org/10.2174/1573394711309010005 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmacological Approaches in an Experimental Model of Non-Small Cell Lung Cancer: Effects on Tumor Biology
Current Pharmaceutical Design DNA Microarray-Based Gene Expression Profiling in Cancer: Aiding Cancer Diagnosis, Assessing Prognosis and Predicting Response to Therapy
Current Pharmacogenomics Pharmacogenetics of Phase I and Phase II Drug Metabolism
Current Pharmaceutical Design Current Development of ROS-Modulating Agents as Novel Antitumor Therapy
Current Cancer Drug Targets Cognitive Functions under Anti-HER2 Targeted Therapy in Cancer Patients: A Scoping Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Astrocyte Signaling and Multiple Sclerosis
Current Signal Transduction Therapy Novel Neuroendocrine and Metabolic Mechanism Provides the Patented Platform for Important Rejuvenation Therapies: Targeted Therapy of Telomere Attrition and Lifestyle Changes of Telomerase Activity with the Timing of Neuron-Specific Imidazole-Containing Dipeptide-Dominant Pharmaconutrition Provision
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Electro-Organic Synthesis of New Esculetin Derivatives Based on 1,6-Conjugate Addition
Current Organic Chemistry MDR1/P-Glycoprotein (ABCB1) as Target for RNA Interference-Mediated Reversal of Multidrug Resistance
Current Drug Targets Coumarin-Fatty Acid Conjugates as Potential ERα/AKT-1 Antagonists for ER Positive Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Targeting Synthetic Lethality in DNA Damage Repair Pathways as an Anti-Cancer Strategy
Current Drug Targets Small Molecule Toxins Targeting Tumor Receptors
Current Pharmaceutical Design Combretastatin A-4 Analogs as Anticancer Agents
Mini-Reviews in Medicinal Chemistry Development of Novel Rhodanine Analogs as Anticancer Agents: Design, Synthesis, Evaluation and CoMSIA Study
Medicinal Chemistry Anthracyclines: Selected New Developments
Current Medicinal Chemistry - Anti-Cancer Agents Editorial [Hot Topic: The Plasminogen Activation System in Pathology: Use in Prognosis and Therapy (Guest Editor: Marie Ranson)]
Current Drug Targets Weka Machine Learning for Predicting the Phospholipidosis Inducing Potential
Current Topics in Medicinal Chemistry Nanoparticulate Formulations for Paclitaxel Delivery Across MDCK Cell Monolayer
Current Pharmaceutical Design IMPMD: An Integrated Method for Predicting Potential Associations Between miRNAs and Diseases
Current Genomics miR-15b and miR-21 as Circulating Biomarkers for Diagnosis of Glioma
Current Genomics